In the general news, Russia escalated their war inside Syria, sending in soldiers on the ground. In the U.S., record flooding devastated South Carolina. President Obama backed down on his campaign to demand smartphone to make user data available to the DOJ, and the biotech stocks tanked.
In healthcare business news, Express Scripts (ESRX) will add both PCSK9 cholesterol drugs, Praluent and Repatha, to the formulary despite the high costs (AMGN) (REGN). AmerisourceBergen (ABC) acquired the privately held compounding pharmacy ParMEDium. Acorda (ACOR) settled litigation with Allergan (AGN) over drug Ampyra. Lastly, Exact Science’s (EXAS) shares lost more than half their value after the colon cancer test, Colonguard, was not added to a list of screening tests by a panel of experts.
On the data front, Spark Therapeutics’ (ONCE) eye drug SPK-RPE65 succeeded. Immunomedics (IMMU) posted good Phase 2 data on lung cancer drug sacituzumab. Roche’s cobimetinib, a MEK inhibitor, succeeded in Phase 3 melanoma trials. Lastly, Neurocrine’s (NBIX) drug to treat tardive dyskinesia, NBI-98854, succeeded.
From the FDA, Boston Scientific (BSX) received approval for their Synergy stent. Alkermes (ALKS) received approval for antipsychotic Aristada. Lastly, Bristol’s (BMY) Opdivo won expanded approval for lung cancer.